GLENMARK vs HIKAL: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. GLENMARK PHARMACEUTICALS shows a higher ROE, lower leverage and a higher ROCE, while HIKAL shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLENMARK leads 6; HIKAL leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLENMARK | HIKAL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLENMARK | HIKAL |
|---|---|---|
| Live Price | ₹2,198.5 | ₹203.18 |
| Day Change | 0.2% | -3.6% |
| Volume | 5.77 L | 3.29 L |
| 52-Week High | ₹2,537.6 | ₹261 |
| 52-Week Low | ₹1,792.6 | ₹146.25 |
| Distance from 52W High | -13.36% | -22.15% |
Valuation
| Metric | GLENMARK | HIKAL |
|---|---|---|
| Market Cap | ₹61,612 Cr | ₹2,501 Cr |
| P/E Ratio | 41.17x | 0x |
| P/B Ratio | 5.86x | 2.09x |
| EPS | ₹17.11 | ₹-0.6 |
| Book Value | ₹372.49 | ₹97.23 |
| Dividend Yield | 0.11% | 0.28% |
Growth
| Metric | GLENMARK | HIKAL |
|---|---|---|
| Revenue Growth (TTM YoY) | 14.3% | 37.3% |
| EPS Growth (TTM YoY) | 6,575% | 68.3% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | GLENMARK | HIKAL |
|---|---|---|
| ROE | -0.83% | -4.07% |
| ROCE | -0.79% | -0.87% |
| Net Margin | 8.15% | -2.88% |
| Operating Margin | -2.22% | -0.95% |
| Debt to Equity | 0x | 0.57x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLENMARK | HIKAL |
|---|---|---|
| Promoter Holding | 46.65% | 68.85% |
| FII Holding | 20.89%▲ 0.55 pp | 1.27%▲ 0.28 pp |
| DII Holding | 18.6%▼ 0.69 pp | 5.32%▼ 1.92 pp |
| Public Holding | 13.81%▲ 0.13 pp | 24.56%▲ 1.63 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLENMARK PHARMACEUTICALS and HIKAL.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.